[Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy].
D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III; D001777:Blood Coagulation; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D001780:Blood Coagulation Tests; D001791:Blood Platelet Disorders / Q000150:complications; D005164:Factor IX / Q000096:biosynthesis; D005167:Factor VII / Q000096:biosynthesis; D005170:Factor X / Q000096:biosynthesis; D005340:Fibrinogen; D006487:Hemostasis; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011516:Prothrombin / Q000096:biosynthesis; D013916:Thrombelastography; D013917:Thrombin / Q000494:pharmacology; D013925:Thromboplastin / Q000378:metabolism; D013927:Thrombosis / Q000188:drug therapy / Q000503:physiopathology*; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D014812:Vitamin K; D000990:Antithrombin III; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; D005340:Fibrinogen; D006493:Heparin; D013925:Thromboplastin; D013917:Thrombin
Principes du traitement des hypercoagulabilités par une thérapeutique anticoagulante rationnelle.